Trial Profile
An Open-Label, Single Dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of GSK1349572 (Dolutegravir, DTG) in Healthy Japanese Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Aug 2023
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors ViiV Healthcare
- 23 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jun 2011 Actual initiation date (Apr 2011) added according to ClinicalTrials.gov.
- 03 Jun 2011 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.